Puma Biotechnology
Puma catches fifth approval, hunts new indication for Nerlynx
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Puma Biotechnology
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma Biotechnology, Inc. 2020 Current Report 8-K
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Surging
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Pharma (@PumaPharma) / Twitter
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. | LinkedIn
